Eli Lilly and Company enters the molecular glue field making a deal with Magnet worth up to $1.25 billion, and joins other major pharma players. https://lnkd.in/eJVREWmp
关于我们
Endpoints is the biopharma world's leading source for breaking news, smart analysis and exclusive access. We cover the intersection of science, money and power in the world's most innovative industry, and are a part of the Financial Times' FT Specialist group.
- 网站
-
https://endpts.com
Endpoints News的外部链接
- 所属行业
- 在线音视频媒体
- 规模
- 51-200 人
- 总部
- Lawrence，KS
- 类型
- 私人持股
- 创立
- 2014
- 领域
- Biotechnology、News、Drug Development和Pharmaceuticals
地点
-
主要
获取路线
W 24th Pl
US，KS，Lawrence，66049
Endpoints News员工
动态
-
‘We need to sit down with Elon Musk’: The rare disease patients impacted by Trump’s science job cuts https://lnkd.in/eq-eyguG
-
Scoop: Two sources tell Endpoints News that a panel advising the HHS secretary on vaccine injury payouts remains in limbo a month after a scheduled meeting was postponed. https://lnkd.in/e7NjHN8u
-
??????It's time to celebrate and recognize the trailblazers in biopharma. We're now accepting nominations for our annual LGBTQ+ Leaders report, let's honor those who are paving the way for inclusivity and innovation. #LGBTQinBiopharma https://lnkd.in/eTS8ZpSV
-
Can Bill Anderson save Bayer? Andrew Dunn sat down with the Bayer CEO—arguably one of the most difficult jobs in the corporate world—after he left Roche in 2023. https://lnkd.in/eK79SqAr
NEW: Bill Anderson left Roche in 2023 to take one of the most difficult jobs in the corporate world — the CEO of Bayer. The German conglomerate had mountains of debt and massive lawsuits stemming from its 2018 acquisition of Monsanto. Its pharma business relied on two aging blockbusters in Xarelto and Eylea. Fellow countrymates BioNTech SE and Merck KGaA, Darmstadt, Germany are both now more valuable than Bayer, a longtime corporate icon of Deutschland. That tumult has afforded Anderson the chance to try out some new ideas in running a large drugmaker, and I sat down with him to see how the turnaround is going. My latest for Endpoints News explores the big question: Can Anderson save Bayer?
-
Kallyope releases new obesity trial data, showing moderate results for its GLP-1 candidates. It’s also looking into migraine, celiac and allergies as it expands its horizon. https://lnkd.in/enegCs6M
-
BREAKING: In one of biotech's biggest financings of the year so far, Eikon Therapeutics has raised a $351 million Series D. The Bay Area biotech is making its own lab equipment based on Nobel Prize-winning science on super-resolution microscopy. With today's financing, Eikon has now raised over $1.1 billion since its founding in 2019. CEO Roger M. Perlmutter told me that ability to study lit-up proteins inside living cells impacts every part of their drug R&D process, from target selection to hit identification to lead optimization and beyond. Eikon's lead cancer drug, EIK1001, is now starting a Phase 3 study in skin cancer. Within the new few months, the biotech will likely have four drugs in the clinic. “At this early point, these studies are looking very good, and we’re enthusiastic about that and eager to pour fuel on the fire,” Perlmutter told me. My latest for Endpoints News:
-
Some of the more than 200 staffers laid off at the FDA’s Center for Devices and Radiological Health (CDRH) returned to work Monday. https://lnkd.in/eXAjdc26
-
Eikon Therapeutics announced a $351 million Series D round. https://lnkd.in/eSqM52kB
-
AstraZeneca wasn’t expected to have data from the Phase 3 trial of its oral SERD until the second half of this year. https://lnkd.in/ebrTwMc8